AI in Pharma: digital twins as growth factor

Artificial intelligence (AI) has emerged as a transformative force in the pharma industry, revolutionizing various aspects of drug discovery, process development and healthcare delivery. In this video, learn about the use of AI technologies in the pharmaceutical sector, which includes use cases highlighting its potential impact on efficiency, cost-effectiveness and personalized medicine based on digital twins.

The power of combining AI and digital twins to bring new, innovative drugs to patients faster

AI and digital twins are driving transformative change across the pharmaceutical industry. As we face an increasing demand for getting new therapies to patients faster, these technologies pave the way for innovation and efficiency. AI has significantly sped up drug discovery processes. For example, during the COVID-19 pandemic, an AI system identified a potential drug candidate in just 48 hours. The ability of AI to mine vast datasets quickly and accurately is revolutionizing how drug discovery and development is approached.

Future prospects and ethical considerations of AI and digital twins in innovation

In the future, we’ll be able to create digital twins of patients to support personalized medicine. However, this advancement introduces new challenges. Key issues include breaking down data silos, ensuring data quality, and addressing privacy and ethical concerns. Recognizing these challenges, the FDA has developed an action plan and committed to an ongoing strategy for effective data management.

Watch the video and learn about the synergy between digital twins and AI in advancing pharmaceutical innovations.